Comparison of Triamcinolone Versus Platelet Rich Plasma Injection for Improving Trismus in Oral Submucous Fibrosis
DOI:
https://doi.org/10.51985/JBUMDC2019104Keywords:
Injection, Oral Sub Mucosal Fibrosis, Platelet rich Plasma, Trismus, Triamcinolone.Abstract
Objective: To compare the effect of Triamcinolone versus Platelet Rich Plasma (PRP) injection intraorally for improving
trismus in Oral Submucous Fibrosis (OSMF).
Study Design and setting: Randomized double-blind comparative study, conducted at ENT department of PNS Shifa
Hospital, Karachi from 1st June 2015 to 30th June 2016.
Methodology: Eighty patients with trismus due to oral submucous fibrosis were divided randomly into two groups, ‘A’
and ‘B’ of 40 patients each. In Group A, Inj. Triamcinolone 40mg (1 ml) was injected into the sub-mucosal plane in the
retro-molar trigone area and into the fibrous bands along the soft palate on multiple sites, weekly for 6 weeks. In group B
Inj. PRP 1ml weekly was administered for 6 weeks along the same site. Vernier calipers were used to precisely measure
the Maximum Interincisal Distance (MIID) in cms before and after the treatment.
Result: There was a male preponderance in the study group with a male to female ratio of 5.1:1. In group ‘A’ mean pretreatment
MIID was 2.3±0.7 cms, while in group ‘B’, it was 2.2± 0.5 cms. After completion of 6 weeks treatment the mean
MIID improved in group ‘A’ to 3.08 ± 0.8cms, and in group ‘B’ to 3.22± 0.5cms. The mean improvement in MIID in group
‘A’ was 0.783± 0.25cms compared to 1.01± 0.05 cms in group ‘B’ (p < 0.05).
Conclusion: Intraoral injection of PRP is more effective than Triamcinolone in improving trismus due to OSMF.
References
Ray JG, Ranganathan K, Chattopadhyay A. Malignant
transformation of oral submucous fibrosis: Overview of
histopathological aspects. Oral Surg Oral Med Oral Pathol
Oral Radiol. 2016;122:200–9.
Chattopadhyay A, Ray JG. Molecular pathology of malignant
transformation of oral submucous fibrosis. J Environ Pathol
Toxicol Oncol. 2016;35:193–205.
Rajendran R. Oral submucous fibrosis: etiology, pathogenesis
and future research. WHO Bull OMS. 1994;72(6):986–996
Murti P.R., Bhonsle R.B., Gupta P.C., Daftary D.K., Pindborg
J.J., Mehta F.S. Etiology of oral submucous fibrosis with
special reference to the role of areca nut chewing. J Oral
Pathol Med. 1995; 24(4):145–152.
Babu S., Bhat R.V., Kumar P.U. A comparative clinicopathological
study of oral submucous fibrosis in habitual
chewers of pan masala and betel quid. Clin Toxicol. 1996;
:317–322.
Auluck A, Rosin MP, Zhang L. Oral Submucous Fibrosis; a
clinically benign but potentially malignant disease: Report of
cases and review of literature. www.cda-adc.ca/jcda/vol-
/issue-8/735.html [PUBMED]
Chole RH, Gondivkar SM, Gadbail AR, Balsaraf S, Chaudhary
S, Dhore SV, et al. Review of drug treatment of oral submucous
fibrosis. Oral Oncol. 2012; 48:393–8.
Pandya S, Chaudhary AK, Singh M, Singh M, Mehrotra R.
Correlationof histopathological diagnosis with habits and
clinical findings in oralsubmucous fibrosis. Head Neck Oncol.
; 1:10.
Ceena DE, Bastian TS, Ashok L, Annigeri RG. Comparative
study ofclinic functional staging of oral submucous fibrosis
with qualitativeanalysis of collagen fibers under polarizing
microscopy. Indian J DentRes. 2009; 20(3):271–276.
Patil S, Maheshwari S. Proposed new grading of oral
submucous fibrosisbased on cheek flexibility. J Clin Exp
Dent. 2014; 6(3):e255–e258.
Gupta M, Pachauri A, Singh SK, Ahuja R, Singh P, Mishra
SSS. Recent Advancements in Oral Submucous Fibrosis
Management: An Overview. Bangladesh J Dent Res Educ.
; 4(2):88-90.
Albanese A, Licata ME, Polizzi B, Campisi G. Platelet-rich
plasma (PRP) in dental and oral surgery: from the wound
healing to bone regeneration. Immun Ageing. 2013;10(1):23.
Lin SL, Tsai CC, Wu SL, Ko SY, Chiang WF, Yang JW. Effect
of athrocentesis plus platelet-rich plasma and platelet-rich
plasma alone in the treatment of temporomandibular joint
osteoarthritis: A retrospective matched cohort study. Medicine
(Baltimore)2018;97(16):e0477.
Marx RE. Platelet-rich plasma: evidence to support its use.
J Oral Maxillofac Surg 2004; 62:489-96.
Dyavanagoudar SN (2009) Oral Submucous Fibrosis: Review
on Etiopathogenesis. J Cancer Sci Ther 1: 072-077.
doi:10.4172/1948-5956.1000011[Internet]
Yoithapprabhunath TR, Maheswaran T, Dineshshankar J,
Anusushanth A, Sindhuja P, Sitra G. Pathogenesis and
therapeutic intervention of oral submucous fibrosis. J Pharm
Bioallied Sci. 2013; 5(Suppl 1): S85–S88.
Chole RH, Patil R. Drug treatment of oral sub mucous fibrosis
– a review. Intl J Contemp Med Resr. 2016;3(4):996-998.
James L, Shetty A, Rishi D, Abraham M. Management of
Oral Submucous fibrosis with Injection of Hyaluronidase and
Dexamethasone in grade III Oral Submucous fibrosis: A
retrospective study. J Int Oral Health 2015; 7(8):82-85.
Gupta J, Srinivasan SV , Jonathan D M. Effiacy of
betamethasone, placental extract and hyaluronidase in the
treatment of OSMF: A comparative study. e-Journal
dentistry;2012;2(1).[Internet]
Yadav M, Aravinda K, Saxena VS, Srinivas K, Ratnakar P,
Gupta J, Sachdev AS, Shivhare P. Comparison of curcumin
with intralesional steroid injections in Oral Submucous Fibrosis
– A randomized, open-label interventional study. J Oral Biol
Craniofac Res. 2014; 4(3): 169–173.
Shaikh AH, Ahmed S, Siddique S, Iqbal N, Hasan SMU,
Zaidi SJA, Ali A. Oral submucous fibrosis; Study of cases
reported at Dow international medical college hospital in
karachi, Pakistan. Professional Med J, 2019;26(2):275-81.
Hazarey VK, Erlewad M, Mundhe KA,Ughade SN. Oral
submucous fibrosis: study of 1000 cases from central India.
J Oral Pathol Med 2007; 36: 12–7
Naik SM, Appaji MK, Ravishankara S,Goutham MK, Devi
NP, Mushannavar AS, Naik SS. Comparative study of
intralesional Triamcinolone Acetonide & hyaluronidase vs
Placental extract in 60 cases of Oral submucous fibrosis. Int
J Head Neck Surg 2012; 3(2): 59-65.
Patel TL, Singh S. Comparative evaluation of treatment of
Oral submucous fibrosis with intralesional injections of
Dexamethasone and hyaluronidase with Triamcinolone
Acetonide and hyaluronidase. J Cont Med A Dent 2015;3(3):
-34.
Daga D, Singh RK, Pal US, Gurung T, Gangwar S. Efficacy
of oral colchicine with intralesional hyaluronidase or
triamcinolone acetonide in the Grade II oral submucous
fibrosis. Natl J Maxillofac Surg. 2017;8(1):50-54. doi:
4103/njms.NJMS_5_17.[PUBMED]
Amer Sabih Hydri, Iqbal Hussain Udaipurwala, Nadeem Ahmed Sheikh, Sana Muhammad Sadiq et.al.
JBUMDC2020;10(1):58-62 Page-61
Singh D, Shashikanth MC, Misra N, Agrawal S. Lycopene
and intralesional betamethasone injections in the management
of oral submucous fibrosis . J Indian Acad Oral Med Radiol
[serial online] 2014 [cited 2016 Sep 1];26:264-8. Available
from: http://www.jiaomr.in/text.asp?2014/26/3/264/145000
Ferrari M, Zia S, Valbonesi M. A new technique for
hemodilution, preparation of autologous platelet-rich plasma
and intraoperative blood salvage in cardiac surgery. Int J Artif
Organs. 1987;10:47–50.
Marx RE. In: Tissue Engineering: Applications in Maxillofacial
Surgery and Periodontics. Lynch SE, Genco RJ, Marx RE,
editor. Chicago: Quintessence; 1999. Platelet-rich plasma: a
source of multiple autologous growth factors for bone grafts;
pp. 71–82.
Robert E. Marx, DDS. Platelet-Rich Plasma (PRP): What Is
PRP and What Is Not PRP?Implant Dentistry, 2001; 10(4):
Dayanand AA, Selvam NP. Lycopene in the management of
oral submucous fibrosis. Asian J Pharm Clin Res, 2013; 6(3):
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2020 Amer Sabih Hydri, Iqbal Hussain Udaipurwala, Nadeem Ahmed Sheikh, Sana Muhammad Sadiq, Sohail Aslam, Syed Muhammad Asad Shabbir bukhari
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Journal of Bahria University Medical & Dental College is an open access journal and is licensed under CC BY-NC 4.0. which permits unrestricted non commercial use, distribution and reproduction in any medium, provided the original work is properly cited. To view a copy of this license, visit https://creativecommons.org/licenses/by-nc/4.0 
